The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the lowest cost paid for the same medications in other countries. The steps include providing MFN prices to all Medicaid beneficiaries; requiring manufacturers to stipulate that they will not offer other developed nations better prices for new drugs than those offered in the U.S.; providing manufacturers an avenue to sell medicines directly to patients at a price no higher than the best available in developed nations; and using trade policy to support manufacturers in raising prices internationally provided that higher revenues abroad are reinvested directly into lowering prices for Americans.

Related News Articles

Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The White House yesterday launched TrumpRx, the direct-to-consumer platform that will serve as a hub to direct cash-paying consumers to drug manufacturers…
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…
Headline
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations.…
Headline
The White House released a health care plan Jan. 15 addressing drug prices, health insurance premiums and price transparency efforts. The plan includes…